title: A study of the effect of nasal steroid sprays in perennial allergic rhinitis patients with rhinitis medicamentosa.
abstract: OBJECTIVE
  To determine if rebound congestion can be reduced with concomitant nasal steroid spray usage.
  
  
  METHODS
  Randomized, double blind, controlled single center study.
  
  
  METHODS
  Twenty subjects with perennial allergic rhinitis with nasal congestion.
  
  
  METHODS
  All subjects received 3 weeks of twice-daily oxymetazoline. After 2 weeks, subjects were randomized to 2 additional weeks of concomitant budesonide aqueous nasal spray (n = 9) or placebo (n = 10). In the sixth week, all sprays were stopped.
  
  
  RESULTS
  Both groups showed subjective and objective evidence of rebound congestion 24 hours after cessation of oxymetazoline (P < 0.05). Subjective rebound congestion resolved in 48 hours in the budesonide aqueous nasal spray group but persisted for over 1 week in the placebo group.
  
  
  CONCLUSIONS
  Rebound congestion is objectively present in patients with perennial allergic rhinitis after 3 weeks of oxymetazoline spray. Rebound congestion is reduced by concomitant budesonide aqueous nasal spray use.
  
  
  CONCLUSIONS
  This study supports the common clinical practice of nasal steroid sprays to ameliorate rebound congestion concomitant with and after cessation of topical decongestant sprays.
authors.affiliation: University of Pittsburgh School of Medicine, Eye and Ear Institute and the Department of Otolaryngology, Pennsylvania 15213, USA. bjferg@pitt.edu
authors.forename: B J
authors.initials: BJ
authors.lastname: Ferguson
authors.forename: S
authors.initials: S
authors.lastname: Paramaesvaran
authors.forename: E
authors.initials: E
authors.lastname: Rubinstein
mesh_terms: D000328:Adult; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D019819:Budesonide / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D014663:Nasal Decongestants / Q000009:adverse effects* / Q000627:therapeutic use; D010109:Oxymetazoline / Q000009:adverse effects* / Q000627:therapeutic use; D019141:Respiratory System Agents / Q000627:therapeutic use*; D012221:Rhinitis, Allergic, Perennial / Q000188:drug therapy*
chemical_list: D000893:Anti-Inflammatory Agents; D014663:Nasal Decongestants; D019141:Respiratory System Agents; D019819:Budesonide; D010109:Oxymetazoline